azilsartan medoxomil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 4322 863031-21-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • TAK 491
  • edarbi
  • azilsartan medoxomil
  • azilsartan kamedoxomil
an angiotensin type 1 receptor blocker; receptor blocker
  • Molecular weight: 568.54
  • Formula: C30H24N4O8
  • CLOGP: 5
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 1
  • TPSA: 139.57
  • ALOGS: -4.91
  • ROTB: 10

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 2011 FDA ARBOR PHARMS IRELAND
Dec. 7, 2011 EMA Takeda Pharma A/S
Jan. 18, 2001 PMDA TAKEDA PHARMACEUTICAL COMPANY LIMITED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 68.23 24.93 47 2408 116075 63370492
Hepatic function abnormal 62.78 24.93 30 2425 37112 63449455
Cerebral infarction 55.21 24.93 24 2431 23869 63462698
Renal impairment 54.79 24.93 37 2418 88318 63398249
Hyperkalaemia 36.71 24.93 24 2431 54179 63432388
Decreased appetite 35.54 24.93 46 2409 251006 63235561
Interstitial lung disease 33.81 24.93 24 2431 61884 63424683
Altered state of consciousness 32.61 24.93 17 2438 25213 63461354
Cardiac failure 30.09 24.93 26 2429 89116 63397451
Proteinuria 27.93 24.93 14 2441 19131 63467436
Palmar-plantar erythrodysaesthesia syndrome 25.50 24.93 14 2441 23001 63463566

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 102.43 21.19 49 2951 27406 34926525
Hepatic function abnormal 93.44 21.19 54 2946 44309 34909622
Renal impairment 81.04 21.19 66 2934 94447 34859484
Interstitial lung disease 69.82 21.19 52 2948 65230 34888701
Fibrillary glomerulonephritis 51.65 21.19 8 2992 46 34953885
Proteinuria 42.68 21.19 24 2976 18618 34935313
Decreased appetite 37.89 21.19 58 2942 166334 34787597
Palmar-plantar erythrodysaesthesia syndrome 34.10 21.19 20 2980 16775 34937156
Nephrotic syndrome 33.29 21.19 15 2985 7288 34946643
Thalamus haemorrhage 32.93 21.19 9 2991 996 34952935
Pemphigoid 30.84 21.19 15 2985 8651 34945280
Altered state of consciousness 30.78 21.19 21 2979 22872 34931059
Hepatocellular carcinoma 29.77 21.19 14 2986 7495 34946436
Cardiac failure 28.43 21.19 37 2963 91211 34862720
Thrombotic cerebral infarction 25.33 21.19 6 2994 374 34953557
Anti-neutrophil cytoplasmic antibody positive vasculitis 24.41 21.19 7 2993 922 34953009
Hyperuricaemia 22.98 21.19 12 2988 8031 34945900
Liver disorder 21.98 21.19 20 2980 32977 34920954

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 150.04 18.21 82 5579 73025 79665702
Cerebral infarction 142.55 18.21 68 5593 45608 79693119
Renal impairment 119.92 18.21 95 5566 157688 79581039
Interstitial lung disease 92.41 18.21 71 5590 112529 79626198
Proteinuria 65.32 18.21 36 5625 32466 79706261
Decreased appetite 63.42 18.21 98 5563 342320 79396407
Platelet count decreased 62.63 18.21 73 5588 194591 79544136
Altered state of consciousness 60.32 18.21 38 5623 43784 79694943
Cardiac failure 53.04 18.21 60 5601 154782 79583945
Thalamus haemorrhage 52.04 18.21 14 5647 1768 79736959
Fibrillary glomerulonephritis 51.92 18.21 8 5653 55 79738672
Palmar-plantar erythrodysaesthesia syndrome 48.80 18.21 30 5631 33104 79705623
Hyperkalaemia 43.77 18.21 47 5614 114351 79624376
Liver disorder 41.26 18.21 37 5624 72380 79666347
Malignant neoplasm progression 38.77 18.21 48 5613 135942 79602785
Hyperuricaemia 38.08 18.21 18 5643 11781 79726946
Pemphigoid 36.47 18.21 19 5642 15296 79723431
Aortic dissection 36.46 18.21 13 5648 4162 79734565
Nephrotic syndrome 35.92 18.21 17 5644 11157 79727570
Thrombotic cerebral infarction 34.31 18.21 8 5653 564 79738163
Sinus node dysfunction 31.96 18.21 14 5647 7687 79731040
Hepatocellular carcinoma 29.84 18.21 14 5647 9007 79729720
Blood pressure decreased 29.78 18.21 36 5625 99430 79639297
Renal disorder 29.02 18.21 24 5637 42081 79696646
Hypothyroidism 20.85 18.21 22 5639 52370 79686357
Shunt stenosis 18.74 18.21 6 5655 1385 79737342
Enterocolitis 18.50 18.21 12 5649 14500 79724227
Haemorrhagic cerebral infarction 18.38 18.21 6 5655 1473 79737254
Fulminant type 1 diabetes mellitus 18.37 18.21 6 5655 1477 79737250

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09CA09 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA09 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
FDA PE N0000178477 Decreased Blood Pressure
FDA MoA N0000180999 Angiotensin 2 Type 1 Receptor Antagonists
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:61016 angiotensin receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Hypovolemia contraindication 28560003
Low blood pressure contraindication 45007003
Hyponatremia contraindication 89627008
Impaired renal function disorder contraindication 197663003
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.11 acidic
pKa2 3.02 Basic
pKa3 2.4 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 40MG MEDOXOMIL EDARBI AZURITY N200796 Feb. 25, 2011 RX TABLET ORAL 7572920 Jan. 7, 2025 TREATMENT OF HYPERTENSION
EQ 80MG MEDOXOMIL EDARBI AZURITY N200796 Feb. 25, 2011 RX TABLET ORAL 7572920 Jan. 7, 2025 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;12.5MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 7572920 Jan. 7, 2025 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 7572920 Jan. 7, 2025 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;12.5MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 9387249 July 1, 2031 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 9387249 July 1, 2031 TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST IC50 8.13 IUPHAR CHEMBL
Type-1 angiotensin II receptor GPCR IC50 6.38 CHEMBL

External reference:

IDSource
D08067 KEGG_DRUG
863031-24-7 SECONDARY_CAS_RN
4030593 VANDF
4030594 VANDF
C2698291 UMLSCUI
CHEBI:68845 CHEBI
CHEBI:68850 CHEBI
CHEMBL2028661 ChEMBL_ID
CHEMBL2103795 ChEMBL_ID
DB08822 DRUGBANK_ID
C557413 MESH_SUPPLEMENTAL_RECORD_UI
C521273 MESH_SUPPLEMENTAL_RECORD_UI
6900 IUPHAR_LIGAND_ID
8874 INN_ID
LL0G25K7I2 UNII
135409642 PUBCHEM_CID
1091642 RXNORM
180314 MMSL
27787 MMSL
d07754 MMSL
013661 NDDF
013662 NDDF
448917007 SNOMEDCT_US
449042005 SNOMEDCT_US
449561004 SNOMEDCT_US
C1958569 UMLSCUI
CHEMBL57242 ChEMBL_ID
8724 INN_ID
147403-03-0 SECONDARY_CAS_RN
135415867 PUBCHEM_CID
6901 IUPHAR_LIGAND_ID
F9NUX55P23 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Edarbi HUMAN PRESCRIPTION DRUG LABEL 1 60631-040 TABLET 40 mg ORAL NDA 32 sections
Edarbi HUMAN PRESCRIPTION DRUG LABEL 1 60631-040 TABLET 40 mg ORAL NDA 32 sections
Edarbi HUMAN PRESCRIPTION DRUG LABEL 1 60631-080 TABLET 80 mg ORAL NDA 32 sections
Edarbi HUMAN PRESCRIPTION DRUG LABEL 1 60631-080 TABLET 80 mg ORAL NDA 32 sections
Edarbyclor HUMAN PRESCRIPTION DRUG LABEL 2 60631-412 TABLET 40 mg ORAL NDA 32 sections
Edarbyclor HUMAN PRESCRIPTION DRUG LABEL 2 60631-412 TABLET 40 mg ORAL NDA 32 sections
Edarbyclor HUMAN PRESCRIPTION DRUG LABEL 2 60631-425 TABLET 40 mg ORAL NDA 32 sections
Edarbyclor HUMAN PRESCRIPTION DRUG LABEL 2 60631-425 TABLET 40 mg ORAL NDA 32 sections